Stuttgart
03.07.26 | 21:56
3,960 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,080 | 4,140 | 04.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | ASCENTAGE (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION ... | 1 | HKEx | ||
| 15.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress | 2 | GlobeNewswire (USA) | ||
| 15.06. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES MULTIPLE CLINICAL UPDATES AT EHA2026 CONGRESS | 2 | HKEx | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.06. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 10.06. | B.Riley initiates Ascentage Pharma stock with buy, $45 target | 1 | Investing.com | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 27.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 27.05. | ASCENTAGE-B (06855): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER | - | HKEx | ||
| 22.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | 211 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 22.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST CLINICAL DATA FROM MULTIPLE TRIALS AT ASCO 2026 | 1 | HKEx | ||
| 21.05. | ASCENTAGE-B (06855): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 20.05. | ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026 | 1 | HKEx | ||
| 18.05. | TGI Solar Power Group, Inc.: TGI Solar Power Group CEO Samuel Epstein Elected Secretary/Editor of AAPG House of Delegates; Company Accelerates AXINOD Sovereign AI Strategy | 414 | ACCESS Newswire | Company Concurrently Signals Expansion into High-Growth Sovereign AI Market with AXINOD Modular Infrastructure Strategy MIAMI, FL / ACCESS Newswire / May 18, 2026 / TGI SOLAR POWER GROUP INC. (OTC Markets:TSPG)... ► Artikel lesen | |
| 14.05. | Ascentage Pharma: Interview With Co-Founder & CEO Dr. Dajun Yang About The Global Hematology-Oncology Company | 4 | pulse2.com |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,30 | -0,18 % | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| BIOFRONTERA | 2,430 | +4,29 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| OCUGEN | 1,342 | -0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,202 | 0,00 % | Neue Therapeutika, Übernahme und Kurszielerhöhung - BioNxt Solutions, CECONOMY, JD.com, Nordex | Drei aktuelle Börsenszenarien bieten eine klare Investitionschance: Ein innovativer Biotech-Wert punktet durch patentierte Verabreichungstechnologien für Milliardenmärkte - ein vielversprechender Kandidat... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,550 | -0,31 % | Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying | ||
| INFLARX | 2,028 | -2,31 % | InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient... ► Artikel lesen | |
| EDITAS MEDICINE | 3,120 | -1,89 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,676 | +0,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility | -Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth- -Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,760 | -0,24 % | Regulatory tracker: FDA sets decision date for Sarepta's DMD drugs | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| BASILEA | 59,00 | +0,17 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,200 | -1,18 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,88 | +0,65 % | Chardan: Arrowhead Pharmaceuticals ist Top-Pick im Biotech-Sektor vor wichtigen Daten | ||
| ATAIBECKLEY | 4,360 | -1,80 % | AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs | ||
| ALDEYRA | 2,060 | 0,00 % | Aldeyra appoints Darlene Deptula-Hicks to board of directors |
ASCENTAGE PHARMA GROUP INTERNATIONAL gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.